Company intelligence / Profile preview

Dalim Biotech

Wonju, Gangwon, South Korea

Ownership: Private
Development stage: Commercial

Overview

Dalim Biotech manufactures and markets pharmaceutical products targeting chronic diseases including endocrinopathies and menopause-related disorders. The company also sponsors clinical research on vitamin D supplementation to prevent postoperative hypocalcemia following thyroid surgery. At least one clinical trial has reached Phase 4 status.

Therapeutic areas: OtherEndocrinology
Modalities: Small moleculesvitamin D supplementation
Industry: Biotech

Drug pipeline

1 asset

Tetronine

Partnerships

Collaborated with National Cardiovascular Center Harapan Kita Hospital Indonesia on at least one clinical study.

Beyond the preview

Go deeper on Dalim Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dalim Biotech.

Explore the full profile